Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
95% Efficacy overall for prevention of severe COVID-19 disease including related deaths 55% Efficacy overall for preventing symptomatic COVID-19 disease...






